5 completed, 2 active not recruiting, 2 recruiting. 9 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 5, Active not recruiting 2, Recruiting 2 |
Follow Abuse, Drug: new trials by email Literature Review of Abuse, Drug trials Research Report on Abuse, Drug
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| THC and CBD: A Controlled Human Study Probing a Harm Reduction Strategy Placebo, THC, CBD 20 mg - Abuse, Drug, Pain | Phase 1 | Recruiting | University of California, Los Angeles | 30 | 2025-11-05 | 2025-12-17 |
| Age-dependent Effects of Smoked and Oral Delta-9-THC Cannabis, Dronabinol, Smoked Placebo - Pain, Abuse, Drug | Phase 1 | Recruiting | University of California, Los Angeles | 103 | 2025-04-30 | 2026-01-07 |
| A Study to Assess the Abuse Potential of Intranasal Cebranopadol Cebranopadol- 600 ug, Cebranopadol- 800ug, Cebranopadol- 1000ug - Abuse, Drug | Phase 1 | Completed | Tris Pharma, Inc. | 48 | 2024-06-28 | 2025-12-18 |
| AnalgeSiC and appEtite-stimulating Effects of caNnabigerol and THC (ASCENT) Placebo, Low CBG, High CBG - Pain, Appetite Loss | Phase 1 | Active not recruiting | University of California, Los Angeles | 20 | 2023-02-15 | 2026-03-20 |
| Analgesic and Subjective Effects of Terpenes Low THC, High THC, Low Myrcene - Pain, Abuse, Drug | Phase 1 | Active not recruiting | University of California, Los Angeles | 45 | 2021-12-15 | 2026-09-08 |
| Cannabis Effects as a Function of Sex Active Cannabis, Placebo Cannabis - Pain, Abuse, Drug | Phase 1 | Completed | University of California, Los Angeles | 161 | 2021-07-08 | 2026-10-27 |
| Effects of Cannabis on Prescription Drug Abuse Liability and Analgesia Oxycodone, Cannabis (THC:CBD = ~ 1:0), Cannabis (THC:CBD = ~ 0:1) - Pain, Abuse, Drug | Phase 1 | Completed | New York State Psychiatric Institute | 26 | 2019-04-01 | 2024-12-05 |
| Abuse Potential of Intravenous Remimazolam Compared to Midazolam and Placebo in Recreational CNS Depressant Users Remimazolam, Midazolam, Saline - Abuse, Drug | Phase 1 | Completed | Paion UK Ltd. | 83 | 2015-06-23 | 2019-10-01 |
| A Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid Users Cebranopadol 100 micrograms, Cebranopadol 400 micrograms, Hydromorphone hydrochloride 4 milligrams - Abuse, Drug | Phase 1 | Completed | Tris Pharma, Inc. | 226 | 2013-04-15 | 2021-07-15 |
Substance-Related Disorders (9) · Pain (6) · Marijuana Abuse (5) · Agnosia (2) · Anorexia (1) · Coitus (1)
Chemically-Induced Disorders (9) · Mental Disorders (9) · Neurologic Manifestations (6) · Pathological Conditions, Signs and Symptoms (6) · Signs and Symptoms (6) · Nervous System Diseases (2) · Neurobehavioral Manifestations (2) · Perceptual Disorders (2) · Behavior (1) · Sexual Behavior (1) · Signs and Symptoms, Digestive (1)
nabiximols (3) · Dronabinol (2) · 6'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine (1) · Hydromorphone (1) · Midazolam (1) · Oxycodone (1) · Sodium Chloride (1) · remimazolam (1)
University of California, Los Angeles (5) · Tris Pharma, Inc. (2) · New York State Psychiatric Institute (1) · Paion UK Ltd. (1)
United States (8) · Canada (1)
Ziva Cooper, PhD (4) · Angela Eakin, MD (1) · Caroline A Cooper, PhD (1) · Shawn Searle, MD (1) · Ziva D Cooper, PhD (1)
R01AT010762 (1), R01DA047296 (1), R01DA057252 (1)